April 2012

November 2008 US clinical trial update

United States

Dasatinib Phase 2: This trial has been on-going for over a year. Initially the trial was for 12 different types of sarcoma; GIST has recently been added to the list of conditions that will be accepted for this oral drug. Dasatinib (BMS-354825) was tried in GIST in a Phase 1 trial in 2004 and 2005 for patients failing imatinib. At ASCO 2005, it was reported that nine GIST patients entered the trial and had mixed results. Since that time recent publications indicate that Dasatinib is a potent in vitro inhibitor of several GIST mutations. These have highlighted the potential of Dasatinib as a second and third line drug especially for PDGFRA mutation GIST. Patients must have failed imatinib to enter this trial. Prior treatment with sunitinib is not required. This trial is open in 12 states and the District of Columbia.

OSI-930 Phase 1: No longer recruiting.

International

Nilotinib Phase 2: Novartis has opened a front line study of Nilotinib for GIST in Bad Saarow, Germany. Patients with unresectable GIST will be given Nilotinib instead of Glivec. Participants may not have had prior nilotinib. This trial plans to accrue 40 patients over the next year. Contact: Novartis Basel + 41 61 324 1111. NCT # 00756509. Novartis internal # CAMN107DDE06. EUDRACT- Nr. 2008-000358-11.

Go to the LRG Clinical Trials Database for the latest updates on clinical trials.